So, how much do you know about bispecific therapy?
Can you even offer a passing definition?
Well, read on dear reader….. and learn enough to impress your colleagues!
Why is knowing about bispecific therapies even remotely important?
Although they have been around for more than a decade, bispecifics are back and making big news in disease management. Currently, there are over 100 bispecifics in clinical development. AstraZeneca, BioNTech and Summit Therapeutics are just a few pharma with pipeline products. KOLs believe that bispecifics are the next new thing in immunotherapy with promise to even surpass the pioneering performance of monoclonal antibody therapy Keytruda.
Here’s the definition that you need to know to sound well informed……
Bispecific antibodies are engineered to bind to cancer cells and healthy immune system cells (T-cells) at the same time, activating the healthy immune system cells to recognize and destroy cancerous cells.
The article below does a good job of filling in more detail to assuage your insatiable curiosity.
——————————————————————————————–
With Myriad Recent Approvals in Cancer, The Era of Bispecifics Is Here
As companies roll out data showing the power and improved safety profile of antibodies that target two antigens, analysts say the class could overtake monoclonal antibody Keytruda as the “immunotherapy backbone” of solid tumor treatment.
